Rein Therapeutics (NASDAQ: RNTX) announced that its Phase 2 RENEW clinical trial is now enrolling patients across all five planned ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE